Visionix and iCare have officially combined their ophthalmic medical device and imaging portfolios, following Revenio Group Corporation's acquisition of Visionix. This merger creates a more comprehensive product range spanning diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions, offering overseas distributors and clinic buyers access to a wider array of integrated technologies for eyecare professionals.
Merger details
Revenio, iCare's Finnish parent company, purchased Visionix's entire capital share from French parent LT International SAS. The integration process has been ongoing, with customer contacts and support channels remaining unchanged. The companies emphasize that this partnership brings together complementary businesses to strengthen their global presence.
Visionix product portfolio
Visionix, headquartered in France with a U.S. arm in Illinois, offers integrated technologies for optometry, ophthalmology, and optical fields. Key products include autorefractors, autolensmeters, clinical pre-test instruments, OCT/OCTA devices, fundus cameras, lens edgers, refraction equipment, and slit lamps. Notable brands include Briot (lens edging), Optuvue (OCT/OCTA), Visionix (diagnostic instruments), and Weco (lab equipment).
iCare product line
iCare, operating under Revenio, specializes in medical devices for screening and diagnosing ocular diseases. Its portfolio includes fundus perimeters, microperimeters, retinal imaging, rebound tonometers, and other solutions. These devices complement Visionix's offerings, particularly in diagnostic and screening capabilities.
Combined offering benefits
The merged portfolio spans diagnostics, imaging, refraction, OCT, software, and AI-enabled connected workflow solutions. As Revenio CEO Jouni Toijala stated: "We are creating a stronger company with broader capabilities, greater scale, and a highly comprehensive offering for eyecare professionals globally." This expansion aims to increase access for customers and partners.
What buyers should watch
Distributors and clinic buyers should monitor how the combined portfolio integrates across regions, especially in the U.S. and Europe. The unchanged customer support channels suggest continuity, but the broader product range may offer new bundling opportunities for clinics seeking comprehensive ophthalmic solutions.
Source: Read the original report | Published: June 02, 2026